Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress June 1, 2026 7:00 AM EDT
Company Participants
Dave Gancarz – Chief Business & Strategy Officer
Howard West – Vice President of Clinical Development
Allen Yang – Head of R&D Strategy
Bilal Piperdi
Conference Call Participants
Tyler Van Buren – TD Cowen, Research Division
Salveen Richter – Goldman Sachs Group, Inc., Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
Bradley Canino – Guggenheim Securities, LLC, Research Division
Mohit Bansal – Wells Fargo Securities, LLC, Research Division
Reni Benjamin – Citizens JMP Securities, LLC, Research Division
Xiaochuan Dai – UBS Investment Bank, Research Division
Dara Azar – Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Operator
Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Summit Therapeutics ASCO 2026 Update Call. [Operator Instructions] I would now like to turn the call over to Dave Gancarz, Chief Business and Strategy Officer. Please go ahead.
Dave Gancarz
Chief Business & Strategy Officer
Good morning, and thank you for joining us. Team Summit is pleased to be hosting this call from Chicago, where the oncology community has gathered for what has already been an exciting ASCO 2026 Congress. This meeting continues to showcase the rapid pace of innovation across cancer research and treatment, and we’re energized to be a part of this important scientific and clinical discussion directing the next wave of medicines for patients with cancer.
We issued 2 press releases over the weekend relating to encouraging Phase II data in metastatic colorectal cancer and, of course, the historic results of the Phase III HARMONi-6 trial featuring Ivonescimab presented as part of yesterday’s plenary session at ASCO. The Phase II CRC data is a global data set, including patients
